🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Haeseong Park

Brigham and Women's Hospital

ORCID: 0000-0002-3430-8463

Also affiliated with Harvard University, Washington University in St. Louis, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Supplementary Data from First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

Figshare(2023)10.1158/1078-0432.22487576.v1
Top 100%
0DataRank
Top 100%0 citations

Justin F. Gainor, Margaret K. Callahan, Gerald S. Falchook, Russell K. Pachynski, Patricia LoRusso +29 more

Papers

Driven by 19 papers — median percentile 0. Top paper: “Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial”.

Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial

The Lancet Oncology(2022)10.1016/s1470-2045(21)00658-6
N/A
4.8DataRank · unranked
234 citations

Anita Giobbie‐Hurder, Srinika Ranasinghe, Katrina Kao, Ana Lako, Junko Tsuji +32 more

Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-1215
N/A
1.3DataRank · unranked
41 citations

Haeseong Park, S. Greg Call, Kiran Madwani, Yasuhiro Oki, Vivek Subbiah +17 more

Manufacturing‐dependent change in biological activity of the TLR4 agonist GSK1795091 and implications for lipid A analog development

Clinical and Translational Science(2022)10.1111/cts.13387
N/A
0.655DataRank · unranked
16 citations

Aaron R. Hansen, Glenn J. Hanna, Elena Garralda, Haeseong Park, James Strauss +11 more

COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials

Nature Reviews Clinical Oncology(2021)10.1038/s41571-021-00487-z
N/A
0DataRank · unranked
140 citations

Justin F. Gainor, Aparna Hegde, Alison M. Schram, Giuseppe Curigliano, Sumanta K. Pal +19 more

Complete remission in a patient with widely metastatic HER2-amplified pancreatic adenocarcinoma following multimodal therapy informed by tumor sequencing and organoid profiling

medRxiv(2021)10.1101/2021.12.16.21267326
N/A
0DataRank · unranked
1 citations

Amber R. Smith, Gino Pineda, Michitaka Nakano, Flavia Michelini, S. Peter Goedegebuure +28 more

First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-4256
N/A
0DataRank · unranked
98 citations

Justin F. Gainor, Margaret K. Callahan, Gerald S. Falchook, Russell K. Pachynski, Patricia LoRusso +29 more

Context-dependent activation of STING-interferon signaling by CD11b agonists enhances anti-tumor immunity

Cancer Cell(2023)10.1016/j.ccell.2023.04.018
N/A
0DataRank · unranked
95 citations

Graham D. Hogg, Chong Zuo, Nicholas Borcherding, John Baer, Varintra E. Lander +15 more

Transferrin receptor in primary and metastatic breast cancer: Evaluation of expression and experimental modulation to improve molecular targeting

PLoS ONE(2023)10.1371/journal.pone.0293700
N/A
0DataRank · unranked
24 citations

Alison K. Esser, Christopher Egbulefu, Partha Karmakar, Xinming Su, John S. Allen +13 more

Supplementary Data from First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

Figshare(2023)10.1158/1078-0432.22487576.v1
Top 100%
0DataRank
Top 100%0 citations

Justin F. Gainor, Margaret K. Callahan, Gerald S. Falchook, Russell K. Pachynski, Patricia LoRusso +29 more

Alliance A022102: Randomized phase III trial of mFOLFIRINOX +/- nivolumab vs. FOLFOX +/- nivolumab for first-line treatment of metastatic HER2-negative gastroesophageal adenocarcinoma (GEA).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps4175
N/A
0DataRank · unranked
0 citations

Susan M. Geyer, Kelsey Klute, Jonathan Bleeker, Daniel A. King, Matthew R. Strickland +7 more

PD-L1 has a heterogeneous and dynamic expression in gastric cancer with implications for immunoPET

Frontiers in Immunology(2024)10.3389/fimmu.2024.1405485
N/A
0DataRank · unranked
12 citations

Cristina Simó, Emma Brown, Shayla Shmuel, Sandeep Surendra Panikar, Alex Benton +5 more

Chemical perturbations impacting histone acetylation govern colorectal cancer differentiation

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.12.06.626451
N/A
0DataRank · unranked
2 citations

Zhixin Li, Khoa Doan, Sándor Spisák, Akhouri Kishore Raghawan, Qi Liu +15 more

Chemical Perturbations Impacting Histone Acetylation Govern Colorectal Cancer Differentiation

Gastroenterology(2025)10.1053/j.gastro.2025.07.003
N/A
0DataRank · unranked
3 citations

Zhixin Li, Khoa Doan, Sándor Spisák, Akhouri Kishore Raghawan, Qi Liu +15 more

Modulation of HER2 internalization enhances single-dose antibody-drug potency in HER2+ gastric cancer

Scientific Reports(2025)10.1038/s41598-025-01947-7
N/A
0DataRank · unranked
2 citations

Alex Benton, Emma Brown, Shayla Shmuel, Alex Vanover, Sandeep Surendra Panikar +5 more

VEGFR2 blockade overcomes acquired KRAS G12D inhibitor resistance driven by PI3Kγ activation

bioRxiv (Cold Spring Harbor Laboratory)(2025)10.1101/2025.09.16.676456
N/A
0DataRank · unranked
0 citations

Mingyun Bae, Ji‐Won Kim, Seung Hyup Hyun, Kui‐Jin Kim, Joshua H. Choe +20 more

Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors

Cancer Discovery(2020)10.1158/2159-8290.cd-19-1014
N/A
0DataRank · unranked
356 citations

Hiroji Iwata, Ian E. Krop, Pasi A. Jänne, Toshihiko Doi, Shunji Takahashi +11 more

Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 Studies

Clinical Lung Cancer(2025)10.1016/j.cllc.2025.09.009
N/A
0DataRank · unranked
0 citations

Leena Gandhi, Vignesh Ravichandran, Benjamin Besse, Julien Mazières, Geoffrey I. Shapiro +20 more

Interferon-Induced IDO1 Mediates Radiation Resistance and Is a Therapeutic Target in Colorectal Cancer

Cancer Immunology Research(2020)10.1158/2326-6066.cir-19-0282
N/A
0DataRank · unranked
129 citations

David M. Alvarado, Micah Iticovici, Nathan S. Kau, Haeseong Park, Parag J. Parikh +3 more

Trial in progress: A phase II open-label, randomized study of PARP inhibition (olaparib) either alone or in combination with anti-PD-L1 therapy (atezolizumab) in homologous DNA repair (HDR) deficient, locally advanced or metastatic non-HER2-positive breast cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps1102
N/A
0DataRank · unranked
10 citations

Mary Josephine Paula Pilat, Cesar Augusto Santa-Maria, Roisín M. Connolly, Erin Roesch, Anosheh Afghahi +15 more